LKB1 inhibits the proliferation of gastric cancer cells by suppressing the nuclear translocation of Yap and β-catenin.

Liver kinase B1 (LKB1) is known to suppress the proliferation, energy metabolism and mesenchymal transition of various cancer cells, and is involved in the regulation of Hippo-Yes-associated protein (Yap) and the Wnt/β-catenin signaling pathways. However, the role of LKB1 in gastric cancer (GC) was not fully understood. Thus, in the present study, we studied LKB1 and found that protein expression (0.37±0.061 vs. 0.59±0.108, P=0.006) and the protein ratio of p-Yap/Yap (0.179±0.085 vs. 0.8±0.126, P=0.001) were reduced in 54 gastric adenocarcinoma (GAC) tissues compared with the matched adjacent non-cancerous tissues, using western blotting and RT-qPCR assays. LKB1 expression was also observed decreased in 109 GAC tissues compared with 54 adjacent non-cancerous tissues (χ2=4.678, P=0.0306), and negatively correlated with the nuclear expression of Yap (r=-0.6997) and β-catenin (r=-0.3510), using immunohistochemical analysis. In GC patients, LKB1 expression was negatively associated with tumor size, tumor infiltration, lymph node metastasis and the TNM stage. LKB1 expression was determined to be positively correlated with longer overall survival of GC patients using Kaplan-Meier analysis (P=0.001). Subsequently, LKB1 expression in human GAC AGS cells was enhanced with a full‑length LKB1 transfection. In vitro and in vivo proliferation was inhibited in LKB1-overexpressing GC cells compared with the control cells. Yap and β-catenin expression were assessed by western blotting and RT-qPCR, and were found to be increased in the cytoplasm but decreased in the nucleus in LKB1-overexpressing GC cells compared with the control cells. The increase in cytoplasmic β-catenin was reversed by the silencing of LKB1 or Yap with shRNAs in LKB1-overexpressing GC cells. Moreover, Yap and β-catenin mRNA were barely altered by LKB1 overexpression. Thus, we concluded that LKB1 expression was reduced in GAC tissues but that it correlated positively with better prognosis for GC patients. LKB1 inhibits the proliferation of GC cells by suppressing the nuclear translocation of Yap and β-catenin.

[1]  J. Hung,et al.  Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression , 2014, Oncogene.

[2]  S. Park,et al.  High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer , 2014, PloS one.

[3]  S. Mader,et al.  LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer , 2014, International journal of cancer.

[4]  Yingyong Hou,et al.  YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression , 2014, Nature Communications.

[5]  K. Kaestner,et al.  The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver , 2014, Nature Communications.

[6]  L. Tsai,et al.  LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas , 2014, Oncogene.

[7]  Giuseppe Basso,et al.  YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response , 2014, Cell.

[8]  H. Jeon,et al.  Genetic Variations in STK11,PRKAA1, and TSC1 Associated with Prognosis for Patients with Colorectal Cancer , 2014, Annals of Surgical Oncology.

[9]  H. Ji,et al.  A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.

[10]  W. Hung,et al.  Utilization of Liquid Chromatography Mass Spectrometry Analyses to Identify LKB1–APC Interaction in Modulating Wnt/β-Catenin Pathway of Lung Cancer Cells , 2014, Molecular Cancer Research.

[11]  Kwok-Kin Wong,et al.  A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway , 2013, Nature Cell Biology.

[12]  F. Feo,et al.  Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. , 2013, Journal of hepatology.

[13]  C. Wells,et al.  LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap , 2013, Oncogene.

[14]  Cristian Coarfa,et al.  SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. , 2013, Cell reports.

[15]  Jill P. Mesirov,et al.  β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis , 2012, Cell.

[16]  Joon-Oh Park,et al.  High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma , 2012, PloS one.

[17]  Julia B. Cordero,et al.  Acute WNT signalling activation perturbs differentiation within the adult stomach and rapidly leads to tumour formation , 2012, Oncogene.

[18]  E. Nishida,et al.  A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β‐catenin signalling , 2012, The EMBO journal.

[19]  H. Xi,et al.  Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival , 2012, Journal of Gastroenterology.

[20]  G. Yochum,et al.  Wnt/β-Catenin Signaling Regulates Yes-associated Protein (YAP) Gene Expression in Colorectal Carcinoma Cells* , 2012, The Journal of Biological Chemistry.

[21]  D. Sharma,et al.  Leptin-induced Epithelial-Mesenchymal Transition in Breast Cancer Cells Requires β-Catenin Activation via Akt/GSK3- and MTA1/Wnt1 Protein-dependent Pathways* , 2012, The Journal of Biological Chemistry.

[22]  J. Bader,et al.  Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK , 2011, Nature.

[23]  M. Perez-Moreno,et al.  Epithelial cell polarity, stem cells and cancer , 2011, Nature Reviews Cancer.

[24]  W. Yung,et al.  FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. , 2011, Cancer cell.

[25]  Leah E. Mechanic,et al.  Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer , 2011, Oncogene.

[26]  D. Birnbaum,et al.  Genome profiling of pancreatic adenocarcinoma , 2011, Genes, chromosomes & cancer.

[27]  James F Amatruda,et al.  Genome-Wide RNAi Screen Reveals Disease-Associated Genes That Are Common to Hedgehog and Wnt Signaling , 2011, Science Signaling.

[28]  A. Ashworth,et al.  LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest , 2010, Gastroenterology.

[29]  M. Brown,et al.  YAP Dysregulation by Phosphorylation or ΔNp63-mediated Gene Repression Promotes Proliferation, Survival and Migration in Head and Neck Cancer Subsets , 2010, Oncogene.

[30]  Kwok-Kin Wong,et al.  Somatic LKB1 Mutations Promote Cervical Cancer Progression , 2009, PloS one.

[31]  J. Ptak,et al.  Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers , 2006, Human mutation.

[32]  H. Kuwano,et al.  Clinical significance of mucin phenotype, β‐catenin and matrix metalloproteinase 7 in early undifferentiated gastric carcinoma , 2005, The British journal of surgery.

[33]  R. DePinho,et al.  LKB1 (XEEK1) regulates Wnt signalling in vertebrate development , 2003, Nature Cell Biology.

[34]  M. Stratton,et al.  A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.

[35]  M. Fassan,et al.  High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers , 2013, Gastric Cancer.

[36]  H. S. Kim,et al.  Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. , 2004, European journal of cancer.